Under the approval, the Kit can now be distributed and sold within South Africa. Genedrive products are supplied in the country, and more broadly within Africa, via the Sysmex EMEA organisation.
Since the original evaluation, genedrive has expanded the number of PCR platforms and RNA isolation kit providers which are validated for the Company’s Kit. This is important for markets such as South Africa where high testing volumes are supported by the prevalence of automated/robotic RNA extraction instruments, and the variety of testing platforms is diverse owing to a split between public and private testing facilities.
David Budd, Chief Executive Officer of genedrive plc, said “This is an important milestone in the commercialisation of our COVID-19 Kit in the region. South Africa is a key territory for our distributors and this approval will now provide an acceleration of commercial sales activity in the area.”
